<DOC>
	<DOCNO>NCT00999258</DOCNO>
	<brief_summary>The objective study examine effect allograft function histology convert African American renal transplant recipient chronic allograft nephropathy ( CAN ) tacrolimus-based regimen sirolimus-based maintenance immunosuppression regimen . The investigator hypothesize conversion tacrolimus sirolimus African American renal recipient stabilize improve renal allograft function , stabilize histological progression CAN . This conversion potential prolong long-term graft survival African American renal transplant patient . GFR measurement , histological parameter allograft biopsy , well patient graft survival , incidence acute rejection , specific side effect monitor compare sirolimus conversion group patient maintain tacrolimus .</brief_summary>
	<brief_title>Impact Conversion From Tacrolimus Sirolimus African American Renal Transplant Recipients</brief_title>
	<detailed_description>All African American renal transplant recipient ( &gt; 3months &lt; 5 year post-transplant ) institution currently tacrolimus base regimen screen . Subjects 10 % decrease glomerular filtration rate ( GFR ) baseline , estimate MDRD formula,65 meet inclusion criterion consent enrolled study . Baseline define high GFR estimate MDRD formula , within 3 month transplant . Subjects consent participate study undergo allograft biopsy GFR measurement Gd-DTPA , randomly assign ( 2:1 ) undergo conversion tacrolimus sirolimus continue receive tacrolimus . The subject assign sirolimus conversion group initiate sirolimus 5mg po daily time tacrolimus dose decrease 50 % . Sirolimus level check within week adjust linear fashion achieve trough goal 12-15ng/ml subject within 1 year post-transplant , 8-12 ng/ml subject 1 year post-transplant . Tacrolimus continue subject sirolimus target trough level achieve . Thereafter , tacrolimus discontinue indefinitely . Sirolimus trough level monitor study follow : weekly first month , monthly 1 - 6 month , every 3 month 6 month - 1 year post conversion . Subjects continue receive maintenance immunosuppression consist mycophenolate mofetil 500mg 1000 mg po bid tolerate corticosteroid taper per protocol ( maintenance 2.5mg - 5mg po daily 6 month post-transplant indefinitely ) . GFR measurement DTPA repeat 6 month , 1 year post conversion . The second allograft biopsy perform 1 year sirolimus conversion . The subject assign tacrolimus maintenance group ( control group ) represent present standard care . The subject continue receive prednisone , mycophenolate mofetil , similarly subject assign sirolimus conversion group . In tacrolimus maintenance group , subject monitor accord current clinic protocol , monthly 3 month - 1 year post transplant , every two month second year post-transplant every 3 month 2 year . The tacrolimus dose adjust achieve trough 5-10ng/ml subject randomize control group standard care per protocol . GFR measurement DTPA repeat 6 month , 1 year post randomization . The second allograft biopsy perform 1 year post randomization . Patient graft survival , incidence acute rejection , proteinuria , hyperlipidemia , anemia , leucopenia , thrombocytopenia , clinical parameter monitor compare sirolimus conversion group subject maintain tacrolimus .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>African American ( selfidentified ) renal transplant recipient . Primary retransplant kidneyonly recipient . Recipients tacrolimusbased immunosuppression regimen . Time interval transplant : least 3 month great 5 year . Renal transplant recipient 10 % decrease GFR baseline . Women childbearing potential must negative pregnancy test upon enrollment , must consent receive contraceptive counseling use effective contraception enrol study . Two reliable form contraception must use simultaneously unless abstinence choose method . GFR &lt; 40ml/min . Urine proteintocreatinine ratio &gt; 0.5 . Significant chronic allograft nephropathy grade 3 Banff score . Evidence acute rejection episode within past 3 month . Evidence active infection within past month . Any malignancy except treated nonmelanoma skin cancer within past 3 year . Leucopenia &lt; 2,000/mm3 within past month . Thrombocytopenia &lt; 100,000/mm3 within past month . Total cholesterol &gt; 300mg/dl , despite adequate treatment . Triglycerides &gt; 500mg/dl , despite adequate treatment . Nonhealed postsurgical nonsurgical wound .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>glomerular filtration rate</keyword>
	<keyword>chronic allograft nephropathy</keyword>
	<keyword>Kidney transplantation</keyword>
	<keyword>African American</keyword>
</DOC>